Latest Audit News

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

DorsaVi Limited reported a 5.8% rise in revenue to $1.59 million for FY26 but saw its loss after tax balloon by 462% to $8.52 million, reflecting heavy investment in next-gen semiconductor and AI technologies alongside a $5 million capital raise.

Memphasys Limited (ASX: MEM) reported a significant revenue jump driven by commercialisation of its Felix™ System, narrowing its net loss to $4.1 million for the year ended 30 June 2026.

Mustera Property Group posted a $2.08 million net loss for FY26, weighed down by project costs and inventory write-downs, while making significant progress on its Verse on McCabe development backed by a $74.6 million construction loan.

AIMS Property Securities Fund (ASX:APW) reported a 34% fall in net income for FY26 but saw net asset value rise 16%, supported by strong underlying investment gains and a debt-free balance sheet.

Fat Prophets Global Contrarian Fund Ltd saw a 26% drop in net profit for FY2026 despite an 8% revenue rise, driven by increased performance fees and leveraged portfolio exposure. The fund declared special dividends totaling 7 cents per share and expanded its share capital through recent equity raisings.

Fatfish Group Limited reversed a significant loss to report a small profit for the half-year ending June 2025, while grappling with unresolved allegations of financial misconduct and an auditor's disclaimer of opinion.

La Trobe Private Credit Fund (ASX: LF1) posted a $16 million profit in its inaugural financial year, maintaining steady monthly distributions and executing significant capital management initiatives.

Firebrick Pharma posted a $3.06 million loss for FY26 amid early-stage commercialisation of its Nasodine nasal and throat sprays, while securing $3.17 million through share placements to fund expansion.

Advance ZincTek posted an 11% rise in FY26 profit before tax to $2.247 million on 12.6% higher sales, driven by AI integration and US market strength. The company is set to enter residential battery manufacturing in FY27, leveraging its zinc oxide expertise.

The Calmer Co. International Limited posted a record $8.1 million revenue for FY26, driven by retail and wholesale growth, yet recorded a $3.8 million net loss amid ongoing funding challenges and strategic investments.